218 related articles for article (PubMed ID: 31319966)
21. Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.
Ruan Y; Jiang J; Guo L; Li Y; Huang H; Shen L; Luan M; Li M; Du H; Ma C; He L; Zhang X; Qin S
Sci Rep; 2016 Mar; 6():23368. PubMed ID: 26988277
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
Imai H; Kaira K; Suzuki K; Anzai M; Tsuda T; Ishizuka T; Kuwako T; Naruse I; Nemoto K; Uchino J; Morozumi N; Ishihara S; Minato K; Hisada T
Lung Cancer; 2018 Dec; 126():41-47. PubMed ID: 30527191
[TBL] [Abstract][Full Text] [Related]
23. Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience.
Ricciuti B; Baglivo S; De Giglio A; Chiari R
Ther Adv Respir Dis; 2018; 12():1753466618808659. PubMed ID: 30355049
[TBL] [Abstract][Full Text] [Related]
24. Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.
Tokudome N; Koh Y; Akamatsu H; Fujimoto D; Okamoto I; Nakagawa K; Hida T; Imamura F; Morita S; Yamamoto N
BMC Cancer; 2020 Feb; 20(1):103. PubMed ID: 32028909
[TBL] [Abstract][Full Text] [Related]
25. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
Engle JA; Kolesar JM
Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236
[TBL] [Abstract][Full Text] [Related]
26. Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.
Kobayashi H; Sato K; Niioka T; Miura H; Ito H; Miura M
Clin Lung Cancer; 2015 Jul; 16(4):274-81. PubMed ID: 25554506
[TBL] [Abstract][Full Text] [Related]
27. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
28. Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.
Inoue Y; Morita T; Onozuka M; Saito KI; Sano K; Hanada K; Kondo M; Nakamura Y; Kishino T; Nakagawa H; Ikegami Y
Cells; 2019 Jul; 8(7):. PubMed ID: 31340525
[TBL] [Abstract][Full Text] [Related]
29. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
30. Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Lemos C; Giovannetti E; Zucali PA; Assaraf YG; Scheffer GL; van der Straaten T; D'Incecco A; Falcone A; Guchelaar HJ; Danesi R; Santoro A; Giaccone G; Tibaldi C; Peters GJ
Pharmacogenomics; 2011 Feb; 12(2):159-70. PubMed ID: 21332310
[TBL] [Abstract][Full Text] [Related]
31. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.
Ezeife DA; Melosky B; Tudor R; Lin S; Lau A; Panzarella T; Leighl NB
Curr Oncol; 2018 Oct; 25(5):e385-e390. PubMed ID: 30464688
[TBL] [Abstract][Full Text] [Related]
32. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
33. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer.
Liu G; Cheng D; Ding K; Le Maitre A; Liu N; Patel D; Chen Z; Seymour L; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Feb; 7(2):316-22. PubMed ID: 22237259
[TBL] [Abstract][Full Text] [Related]
35. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
[TBL] [Abstract][Full Text] [Related]
36. Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Rinaldetti S; Pfirrmann M; Manz K; Guilhot J; Dietz C; Panagiotidis P; Spiess B; Seifarth W; Fabarius A; Müller M; Pagoni M; Dimou M; Dengler J; Waller CF; Brümmendorf TH; Herbst R; Burchert A; Janβen C; Goebeler ME; Jost PJ; Hanzel S; Schafhausen P; Prange-Krex G; Illmer T; Janzen V; Klausmann M; Eckert R; Büschel G; Kiani A; Hofmann WK; Mahon FX; Saussele S
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):266-271. PubMed ID: 29510895
[TBL] [Abstract][Full Text] [Related]
37. Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
Yamaguchi O; Kaira K; Mouri A; Shiono A; Hashimoto K; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Cancer Chemother Pharmacol; 2019 May; 83(5):817-825. PubMed ID: 30758646
[TBL] [Abstract][Full Text] [Related]
38. Impact of ABCB1, ABCC1, ABCC2, and ABCG2 variants in predicting prognosis and clinical outcomes of north Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
Sharma P; Singh N; Sharma S
J Gene Med; 2023 Jan; 25(1):e3460. PubMed ID: 36314103
[TBL] [Abstract][Full Text] [Related]
39. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
Hata A; Katakami N; Kaji R; Yokoyama T; Kaneda T; Tamiya M; Inoue T; Kimura H; Yano Y; Tamura D; Morita S; Negoro S; The Hanshin Oncology Group F
Cancer; 2018 Oct; 124(19):3830-3838. PubMed ID: 30192383
[TBL] [Abstract][Full Text] [Related]
40. Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer.
Sano K; Nakadate K; Hanada K
BMC Cancer; 2020 Apr; 20(1):279. PubMed ID: 32252690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
